Evidence map›Paper›PMID 29033582›Full record

ArticleOncoTargets and therapy2017

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.

P Maroto, E Esteban, E Fernández Parra, M J Mendez-Vidal, M Domenech, B Pérez-Valderrama, V Calderero, J L Pérez-Gracia, E Grande, F Algaba

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Loss of Von Hippel-Lindau (International journal of molecular sciences · 2021
    Review
  7. Review
  8. Differential Expression of theFrontiers in cell and developmental biology · 2021
    Article
  9. Review
  10. Molecular Crosstalk Between MYC and HIF in Cancer.Frontiers in cell and developmental biology · 2020
    Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 2 countries.

P MarotoDepartment of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona.
E EstebanDepartment of Oncology, Nuevo HUCA, Oviedo.
E Fernández ParraDepartment of Oncology, H. U. Nuestra Señora de Valme, Sevilla.
M J Mendez-VidalDepartment of Oncology, H. U. Reina Sofía, Córdoba.
M DomenechDepartment of Oncology, Hospital de Althaia Xarxa Asistencial Manresa, Barcelona.
B Pérez-ValderramaDepartment of Oncology, H. U. Virgen del Rocio, Sevilla.
V CaldereroDepartment of Oncology, H. Fundación Miguel Servet, Zaragoza.
J L Pérez-GraciaDepartment of Oncology, Clinica Universitaria de Pamplona, Pamplona.
E GrandeDepartment of Oncology, H. Ramón y Cajal, Madrid.
F AlgabaPathology Unit, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Althaia · ESHospital de Sant Pau · ESHospital Universitario de Valme · ESHospital Universitario Miguel Servet · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen del Rocío · ESInstituto Cajal · ESPuigvert Foundation · ESUniversidad de Oviedo · ESUniversity of Pamplona · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear-cell renal cell carcinoma (ccRCC) is a heterogeneous disease with a different clinical behavior and response to targeted therapies. Differences in hypoxia-inducible factor (HIF) expression have been used to classify von Hippel-Lindau gene (VHL)-deficient ccRCC tumors. c-Myc may be driving proliferation in HIF-2α-expressing tumors in a growth factor-independent manner.

objectiveTo explore the HIF-1α, HIF-2α and c-Myc baseline expression as potential predictors of sunitinib outcome as well as the effectiveness and safety with sunitinib in patients with metastatic ccRCC in routine clinical practice.

methodsThis was an observational and prospective study involving 10 Spanish hospitals. Formalin-fixed, paraffin-embedded primary tumor samples from metastatic ccRCC patients who received sunitinib as first-line treatment were analyzed. Association between biomarker expression and sunitinib treatment outcomes was evaluated. Kaplan-Meier method was applied to measure progression-free survival (PFS) and overall survival.

resultsEighty-one patients were included: median PFS was 10.8 months (95% CI: 7.4-13.5 months), median overall survival was 21.8 months (95% CI: 14.7-29.8 months) and objective response rate was 40.7%, with 7.4% of patients achieving a complete response. Molecular marker staining was performed in the 69 available tumor samples. Significant association with lower PFS was identified for double c-Myc/HIF-2α-positive staining tumors (median 4.3 vs 11.5 months, hazard ratio =2.64, 95% CI: 1.03-6.80,

conclusionThese preliminary results suggest that predictive subgroups might be defined based on biomarkers such as c-Myc/HIF-2α. Further validation with more patients will be needed in order to confirm it. Outcomes with sunitinib in metastatic ccRCC in daily clinical practice resemble those obtained in clinical trials.

Indexed as

clear-cell renal cell carcinomac-MycHIFsunitinib

Identifiers

PMID29033582
PMCPMC5614781
OpenAlexW2755685026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.